Cancer Cell
Volume 21, Issue 1, 17 January 2012, Pages 7-9
Journal home page for Cancer Cell

Preview
How to Fool a Wonder Drug: Truncate and Dimerize

https://doi.org/10.1016/j.ccr.2011.12.017Get rights and content
Under an Elsevier user license
open archive

In a recent paper, Poulikakos et al. describe a new and potentially common mechanism whereby melanomas develop resistance to the BRAF inhibitor vemurafenib by expressing truncated forms of BRAF(V600E) that can dimerize in the absence of activated RAS. Will it be possible to block this with improved BRAF inhibitor design?

Cited by (0)